Floatz logo

Camizestrant

ER+ HER2- Advanced Breast Cancer

AstraZenecaSmall moleculePhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

76 Active assets in the ER+ HER2- Advanced Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Giredestrant
Hoffmann-La Roche
Phase 3BB

View all 50 →

Same molecule, other indications

Camizestrant is also rated in:

breast cancerDormant
BB
Indicative ·
68 / 100
View asset →
ER-Positive HER2-Negative Breast CancerDormant
B
Indicative ·
60 / 100
View asset →
hormone receptor-positive breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →